New Insights into AFib Management: Anticoagulants, Stroke Prevention, and Beyond
Автор: Infinite Pathways Media
Загружено: 2025-11-08
Просмотров: 0
Описание:
Four groundbreaking studies presented at AHA 2025 are revolutionizing the way we approach atrial fibrillation (AFib). The OCEAN study explores the need for ongoing anticoagulation after successful catheter ablation, while ADAPT AF-DES and OPTIMA-AF focus on optimal antithrombotic strategies post-PCI. CLOSURE-AF compares left atrial appendage closure with medical therapy for high-risk patients. Dive into the findings and discover how these trials are reshaping stroke prevention and bleeding risk management in AFib patients.
In OCEAN, rivaroxaban didn't significantly reduce stroke or embolism compared to aspirin, but it increased bleeding risk. ADAPT AF-DES shows non-vitamin K antagonist oral anticoagulants (NOACs) are non-inferior to combination therapy for AFib patients with drug-eluting stents. OPTIMA-AF finds a one-month dual antithrombotic therapy followed by a single clot-preventing medication is as effective as a year-long dual therapy. CLOSURE-AF reveals standard medical therapy, including anticoagulants, is better than left atrial appendage closure for high-risk AFib patients. These studies offer valuable insights for doctors and patients managing AFib.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
